The P024 trial demonstrated that pre-treatment tumor Ki67 levels were not correlated with relapse-free survival (RFS); however, a lower post-treatment Ki67 level was significantly associated with increased RFS [41]. The gene discussed is MKI67; the disease is neoplasm.